SCHEMBL6779219

SCHEMBL6779219

COC(=O)c1cccc(N/C(=N/C#N)SC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.53
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 4/20 0.52
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TP53 P04637 1/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.46
GPR17 Q13304 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779224 1.00 RAB9A (0.53) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL7340642 0.87 HPSE (0.48) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL7340650 0.87 HPSE (0.48) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL23455503 0.82 ALDH1A1 (0.62) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL6777923 0.82 ALDH1A1 (0.62) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL6777924 0.82 ALDH1A1 (0.62) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL6772413 0.81 RAB9A (0.59) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL6772415 0.81 RAB9A (0.59) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL4898452 0.80 TP53 (0.50) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL4898451 0.80 TP53 (0.50) RAB9AALDH1A1NPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0891325-B1 PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2002-02-06 EP disclosed
EP-1157985-A1 Para- substituted phenylene derivatives and their use as integrin antagonists G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6251944-B1 (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY G. D. SEARLE & COMPANY 2001-06-26 US disclosed
EP-0889875-B1 CYCLOPROPYL ALKANOIC ACID DERIVATIVES SEARLE & CO (US) 2001-06-20 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed